Kodiak Sciences (KOD)

Executive Summary

Kodiak Sciences is a clinical-stage biopharmaceutical company specializing in next-generation therapies for retinal diseases, leveraging its proprietary Antibody Biopolymer Conjugate (ABC) platform. The company has pivoted from its earlier anti-VEGF candidate KSI-301 (which faced multiple trial terminations) to a renewed focus on tarcocimab tedromer (a novel anti-VEGF) and KSI-101 (targeting inflammation-driven macular edema). Tarcocimab is currently in a Phase 3 trial for diabetic retinopathy (NCT06270836), which completed enrollment in early 2026, with data readout anticipated in the near term. Additionally, KSI-101 is in a Phase 3 study for macular edema secondary to inflammation (NCT06990399), with topline results expected in 2027. The company also has a Phase 3 combination trial evaluating tarcocimab plus tabirafusp tedromer for wet AMD (NCT06556368). Despite a challenging history with KSI-301, Kodiak's pipeline now targets high-prevalence retinal conditions with differentiated mechanisms. Financially, the company holds a market cap of approximately $2.2 billion, reflecting cautious optimism around its revised strategy and upcoming catalysts. Key risks include clinical execution and competition from established anti-VEGF therapies.

Upcoming Catalysts (preview)

• Q3 2026Tarcocimab Phase 3 Diabetic Retinopathy Data70% success
• 2027KSI-101 Phase 3 Macular Edema Data60% success
• 2027Potential Regulatory Filing for Tarcocimab50% success